Workflow
港股异动 | 药明康德(02359)高开逾7% 前三季度净利润同比增长84.84% 进一步上调全年业绩指引
智通财经网·2025-10-27 01:31

Core Viewpoint - WuXi AppTec (02359) reported strong financial performance for the first three quarters of 2025, with significant revenue and profit growth, indicating a positive outlook for the company's core CRDMO business [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of RMB 32.86 billion, representing a year-on-year increase of 18.6% [1] - The revenue from continuing operations grew by 22.5% year-on-year [1] - The net profit attributable to shareholders reached RMB 12.076 billion, marking an impressive year-on-year growth of 84.84% [1] Future Outlook - The company expects revenue from continuing operations to return to double-digit growth, with the growth rate revised from 13-17% to 17-18% [1] - Overall annual revenue guidance has been raised from RMB 42.5-43.5 billion to RMB 43.5-44 billion [1] Business Focus - The company will concentrate on its core CRDMO business and aims to continuously improve operational efficiency [1] Order Backlog - As of September 30, 2025, the order backlog for continuing operations stood at RMB 59.88 billion, reflecting a year-on-year increase of 41.2% [1] Revenue Breakdown - For the first three quarters of 2025, revenue from continuing operations was RMB 32.45 billion, with contributions from various regions: - Revenue from U.S. clients was RMB 22.15 billion, up 31.9% year-on-year [1] - Revenue from European clients was RMB 3.84 billion, increasing by 13.5% [1] - Revenue from Chinese clients was RMB 5.04 billion, showing a slight growth of 0.5% [1] - Revenue from other regions was RMB 1.42 billion, up 9.2% [1]